Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77858 | 1.00 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL65490 | 1.00 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL222955 | 0.98 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL5898691 | 0.98 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL18358031 | 0.98 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL6219872 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL85536 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67045 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67044 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL27877016 | 0.95 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744549-B | Betulic acid derivant and preparation method thereof and the application in antitumor drug is prepared | 华东师范大学 | 2017-03-29 | — | — | CN | claimed |
| CN-106220607-A | A kind of synthetic method of S 3 (piperidines 2 base) azetidine 3 alcohol | 成都百事兴科技实业有限公司 | 2016-12-14 | — | — | CN | claimed |
| CN-104744549-A | Betulinic acid derivative as well as preparation method and application thereof in preparing antineoplastic drugs | UNIV EAST CHINA NORMAL | 2015-07-01 | — | — | CN | claimed |
| CN-101168514-B | Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity | SHANGHAI YAOMING KANGDE NEW MEDICINE DEVELOPMENT CO., LTD. (CN) | 2011-12-07 | — | — | CN | claimed |
| CN-101168514-A | Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity | SHANGHAI PHARMATECH CO LTD (CN) | 2008-04-30 | — | — | CN | claimed |
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | claimed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | claimed |
| US-12629359-B2 | Structural analogues of methylphenidate as Parkinson's disease-modifying agents | UNIVERSITA' DEGLI STUDI DI BRESCIA (IT) | 2026-05-19 | — | — | US | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| EP-0099056-B1 | N-ACYL DERIVATIVES OF DIPEPTIDES, THEIR MANUFACTURE AND USE IN TREATING DISEASES, AND MEANS THEREFOR | BASF Aktiengesellschaft (DE) | 1987-09-30 | — | — | EP | disclosed |
| EP-0186292-A2 | Tripeptides and sweetening agents containing the same | AJINOMOTO CO., INC. (JP) | 1986-07-02 | — | — | EP | disclosed |
| US-4576749-A | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0099056-A2 | N-acyl derivatives of dipeptides, their manufacture and use in treating diseases, and means therefor | BASF Aktiengesellschaft (DE) | 1984-01-25 | — | — | EP | disclosed |
| US-4225495-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-09-30 | — | — | US | disclosed |
| US-4192945-A | Process for preparing proline and homoproline derivatives | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | HSD17B10 3385/4885SMN1; SMN2 2680/4885RAB9A 1602/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | HSD17B10 3279/4885SMN1; SMN2 2508/4885RAB9A 959/4885 |
| US-12629359-B2 | Structural analogues of methylphenidate as Parkinson's disease-modifying agents | SNCA, SYNJ1, PARK7 | HSD17B10 2720/4885SMN1; SMN2 64/4885RAB9A 842/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | HSD17B10 1168/4885SMN1; SMN2 881/4885RAB9A 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.